Get the Stockscreener App
7.375
0.27%
-0.025
Karyopharm Therapeutics Inc stock is traded at $7.375, with a volume of 382.53K.
It is down -0.27% in the last 24 hours and up +28.35% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$7.40
Open:
$7.4
24h Volume:
382.53K
Relative Volume:
1.69
Market Cap:
$125.75M
Revenue:
$137.27M
Net Income/Loss:
$-123.57M
P/E Ratio:
-0.6695
EPS:
-11.016
Net Cash Flow:
$-102.89M
1W Performance:
+0.96%
1M Performance:
+28.35%
6M Performance:
+68.11%
1Y Performance:
-40.65%
1-Day Range:
$7.295
$7.50
1-Week Range:
$7.01
$7.50
52-Week Range:
$3.51
$12.15
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
7.375 | 126.18M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.85 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.46 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
405.59 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
801.70 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.74 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
MACD Signal: Why Karyopharm Therapeutics Inc stock attracts global investors2025 Winners & Losers & Safe Capital Growth Tips - moha.gov.vn
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Karyopharm Therapeutics (FRA:25K0) EV-to-OCF : -2.79 (As of Dec. 22, 2025) - GuruFocus
Why Karyopharm Therapeutics Inc. (25K0) stock could be next leader2025 Earnings Impact & Growth Focused Investment Plans - Улправда
Can Karyopharm Therapeutics Inc. stock resist sector downturnsJuly 2025 Market Mood & High Accuracy Trade Alerts - Улправда
Is Karyopharm Therapeutics Inc. stock a bargain at current levelsIndustrial Stocks Review & Free Extraordinary Earning Power - bollywoodhelpline.com
How Karyopharm Therapeutics Inc. stock responds to policy changesWeekly Trend Summary & Fast Entry Momentum Alerts - DonanımHaber
Can Karyopharm Therapeutics Inc. stock withstand economic slowdownJuly 2025 Gainers & Precise Swing Trade Entry Alerts - DonanımHaber
Will Karyopharm Therapeutics Inc. stock remain a Wall Street favoriteMarket Activity Recap & Weekly Return Optimization Plans - Улправда
Is Karyopharm Therapeutics Inc. stock attractive for income investors2025 Earnings Impact & Fast Gain Stock Tips - DonanımHaber
Will Karyopharm Therapeutics Inc. (25K0) stock beat international competitionQuarterly Portfolio Review & Accurate Entry/Exit Alerts - Улправда
Piper Sandler names Karyopharm stock as 2026 top pick, maintains $12 target - Investing.com Canada
Karyopharm Therapeutics’ Earnings Call: Progress Amid Challenges - MSN
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Karyopharm to Participate in Baird's Biotech Discovery Series - Karyopharm
Karyopharm (Nasdaq: KPTI) to discuss myelofibrosis in Baird Biotech Discovery Series chat - Stock Titan
Published on: 2025-12-10 09:05:07 - earlytimes.in
Karyopharm Therapeutics (KPTI) Price Target Decreased by 11.70% to 14.11 - MSN
Is Karyopharm Therapeutics Inc. (25K0) stock among top earnings plays2025 Technical Overview & Safe Capital Growth Tips - Newser
How Karyopharm Therapeutics Inc. (25K0) stock reacts to new regulationsTrade Volume Summary & Daily Stock Trend Watchlist - Newser
What makes Karyopharm Therapeutics Inc. (25K0) stock appealing to growth investorsJuly 2025 Volume & Fast Exit and Entry Strategy Plans - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock outperform global peersJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock split increase liquidity2025 Big Picture & Fast Gaining Stock Reports - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock announce special dividendMarket Growth Summary & Expert Curated Trade Ideas - Newser
Why global investors buy Karyopharm Therapeutics Inc. (25K0) stockJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - Newser
Karyopharm Therapeutics (KPTI) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Karyopharm (Nasdaq: KPTI) plans fireside chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference - Karyopharm
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Looking at the Narrative for Karyopharm as Financing and Trial Milestones Shift the Outlook - Yahoo Finance
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Below 200 Day Moving AverageWhat's Next? - MarketBeat
[424B3] Karyopharm Therapeutics Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Is Karyopharm Therapeutics Inc. stock vulnerable to regulatory risks2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Why Karyopharm Therapeutics Inc. (25K0) stock trades below fair valueJuly 2025 Opening Moves & Detailed Earnings Play Strategies - newser.com
How Karyopharm Therapeutics Inc. stock reacts to job market dataStock Surge & AI Driven Price Predictions - newser.com
Is Karyopharm Therapeutics Inc. (25K0) stock undervalued by metrics2025 Investor Takeaways & Daily Stock Trend Watchlist - newser.com
What momentum indicators show for Karyopharm Therapeutics Inc. stockJuly 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Why pension funds invest in Karyopharm Therapeutics Inc. (25K0) stockRate Cut & Technical Pattern Recognition Alerts - newser.com
Can Karyopharm Therapeutics Inc. stock hit record highs againGold Moves & AI Driven Stock Movement Reports - newser.com
Is Karyopharm Therapeutics Inc. stock attractive for long term wealth building2025 Short Interest & Consistent Profit Alerts - newser.com
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Karyopharm Therapeutics Inc Stock (KPTI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Paulson Richard A. | President and CEO |
Sep 15 '25 |
Sale |
6.43 |
1,257 |
8,083 |
84,046 |
| Mano Michael | SVP, General Counsel&Secretary |
Sep 15 '25 |
Sale |
6.43 |
234 |
1,505 |
21,425 |
| Poulton Stuart | EVP, Chief Development Officer |
Sep 15 '25 |
Sale |
6.43 |
401 |
2,578 |
27,710 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Sep 15 '25 |
Sale |
6.43 |
408 |
2,623 |
29,390 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Sep 15 '25 |
Sale |
6.43 |
325 |
2,090 |
35,856 |
| Abate Kristin | Chief Accounting Officer |
Sep 15 '25 |
Sale |
6.43 |
23 |
148 |
10,408 |
| Abate Kristin | Chief Accounting Officer |
Sep 03 '25 |
Sale |
6.78 |
12 |
81 |
9,463 |
| Poulton Stuart | EVP, Chief Development Officer |
Jul 29 '25 |
Sale |
4.37 |
191 |
835 |
27,223 |
| Abate Kristin | Chief Accounting Officer |
Jul 22 '25 |
Sale |
4.00 |
238 |
952 |
9,475 |
| Paulson Richard A. | President and CEO |
May 06 '25 |
Sale |
7.12 |
236 |
1,680 |
82,503 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):